Regeneron

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.

News

Regeneron drug on track to be second FOP treatment

There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

News

Regeneron preps filings for myasthenia gravis drug

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

Regeneron gets long-awaited FDA okay for myeloma drug

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Former CEO wins bidding war for 23andMe, beating Regeneron

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.

Why Regeneron is giving away sequencing “for free”, with Ali...

Regeneron drug on track to be second FOP treatment

Regeneron preps filings for myasthenia gravis drug

Regeneron gets long-awaited FDA okay for myeloma drug

Dupixent is first FDA-approved drug for rare skin disease

Former CEO wins bidding war for 23andMe, beating Regeneron

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Regeneron

Editor's Picks